237 related articles for article (PubMed ID: 18347632)
1. Paracentesis before intravitreal injection of bevacizumab.
Tsui YP; Chiang CC; Tsai YY
Can J Ophthalmol; 2008 Apr; 43(2):239; author reply 239-40. PubMed ID: 18347632
[No Abstract] [Full Text] [Related]
2. Short-term intraocular pressure changes after intravitreal injection of bevacizumab.
Hollands H; Wong J; Bruen R; Campbell RJ; Sharma S; Gale J
Can J Ophthalmol; 2007 Dec; 42(6):807-11. PubMed ID: 18026202
[TBL] [Abstract][Full Text] [Related]
3. Necessity of paracentesis before or after intravitreal injection of bevacizumab.
Huang WC; Lin JM; Chiang CC; Tsai YY
Arch Ophthalmol; 2008 Sep; 126(9):1314-5; author reply 1315. PubMed ID: 18779502
[No Abstract] [Full Text] [Related]
4. Bilateral simultaneous intravitreal injections in the office setting.
Bakri SJ; Risco M; Edwards AO; Pulido JS
Am J Ophthalmol; 2009 Jul; 148(1):66-9.e1. PubMed ID: 19403114
[TBL] [Abstract][Full Text] [Related]
5. Re: Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin).
Utman SA; Dhillon B
Retina; 2008 Apr; 28(4):667; author reply 667-8. PubMed ID: 18398378
[No Abstract] [Full Text] [Related]
6. Bevacizumab local complications.
Gordon-Angelozzi M; Velez-Montoya R; Fromow-Guerra J; García-Aguirre G; Guerrero-Naranjo JL; Quiroz-Mercado H; Morales-Cantón V
Ophthalmology; 2009 Nov; 116(11):2264.e1-3. PubMed ID: 19883862
[No Abstract] [Full Text] [Related]
7. Assessment of anterior chamber inflammation after intravitreal bevacizumab injection in different ocular exudative diseases.
Yeniad B; Ayranci O; Tuncer S; Kir N; Ovali T; Tugal-Tutkun I; Akarcay K
Eur J Ophthalmol; 2011; 21(2):156-61. PubMed ID: 20658459
[TBL] [Abstract][Full Text] [Related]
8. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal bevacizumab.
Lucas RS; McKee HD; Lee LR
Ophthalmology; 2007 Feb; 114(2):400; author reply 400-1. PubMed ID: 17270701
[No Abstract] [Full Text] [Related]
10. Combined cataract extraction and intravitreal bevacizumab in eyes with choroidal neovascularization resulting from age-related macular degeneration.
Furino C; Ferrara A; Cardascia N; Besozzi G; Alessio G; Sborgia L; Boscia F
J Cataract Refract Surg; 2009 Sep; 35(9):1518-22. PubMed ID: 19683147
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal bevacizumab for parapapillary choroidal neovascularization due to exudative age-related macular degeneration.
Jonas JB; Tao Y; Rensch F
Acta Ophthalmol; 2011 Feb; 89(1):e105-7. PubMed ID: 20064119
[No Abstract] [Full Text] [Related]
12. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
Melamud A; Stinnett S; Fekrat S
Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema.
Kumar V; Ghosh B; Raina UK; Goel N
Acta Ophthalmol; 2010 Mar; 88(2):e3; author reply e4. PubMed ID: 19549100
[No Abstract] [Full Text] [Related]
14. Controversies in the treatment of wet age-related macular degeneration.
Moreno SF; Paloma JB
Am J Ophthalmol; 2008 May; 145(5):937; author reply 938. PubMed ID: 18435977
[No Abstract] [Full Text] [Related]
15. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
16. Diffuse diabetic macular oedema treated with intravitreal bevacizumab or triamcinolone acetonide.
Rensch F; Spandau UH; Wickenhäuser A; Jonas JB
Acta Ophthalmol; 2010 Mar; 88(2):e36-7. PubMed ID: 19210330
[No Abstract] [Full Text] [Related]
17. Intravitreal bevacizumab (Avastin) for primary treatment of diabetic macular oedema.
Ozkiriş A
Eye (Lond); 2009 Mar; 23(3):616-20. PubMed ID: 18437176
[TBL] [Abstract][Full Text] [Related]
18. The as-needed treatment strategy for choroidal neovascularization: a feedback-based treatment system.
Spaide RF
Am J Ophthalmol; 2009 Jul; 148(1):1-3. PubMed ID: 19540983
[No Abstract] [Full Text] [Related]
19. Case of anterior uveitis after intravitreal injection of bevacizumab.
Pieramici DJ; Avery RL; Castellarin AA; Nasir MA; Rabena M
Retina; 2006 Sep; 26(7):841-2. PubMed ID: 16963867
[No Abstract] [Full Text] [Related]
20. Anti-VEGF therapy: riding the wave of change.
Hunyor AP
Clin Exp Ophthalmol; 2008 Jul; 36(5):401-2. PubMed ID: 18925912
[No Abstract] [Full Text] [Related]
[Next] [New Search]
